Insider · CIK 0001278219
Lota S. Zoth
director
Files at INO (INOVIO PHARMACEUTICALS, INC.), LUMOS PHARMA, INC., ETNB (89bio, Inc.), ENGN (enGene Holdings Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Jun 16, 2025 | ENGN enGene Holdings Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| May 21, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +2,167 | - | - | 8,726 | May 21, 2025 |
| May 21, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -2,167 | $0.00 | $0 | 0 | May 21, 2025 |
| Feb 3, 2025 | ETNB 89bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +56,400 | $0.00 | $0 | 56,400 | Feb 5, 2025 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Common Stock | -2,187 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,345 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,328 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,684 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,431 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,910 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,777 | - | - | 0 | Dec 13, 2024 |
| Dec 12, 2024 | - LUMOS PHARMA, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,324 | - | - | 0 | Dec 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.